Exelixis | EXEL - Assets


Exelixis reported $2.59B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Akebia Therapeutics USD 362.52M 14.04M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Eisai JPY 1.45T 37.11B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Exelixis USD 2.59B 250.83M Mar/2026
Genmab DKK 12.87B 5.85B Dec/2025
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Moderna USD 11.49B 850M Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Takeda JPY 15.45T 44.34B Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Xencor USD 736.85M 138.65M Mar/2026